Phathom Pharmaceuticals snatches up another Celgene exec; True North bets $74M for a stake in Biocon Biologics
→ Ahead of the potential commercialization of vonoprazan, gastrointestinal disease-focused Phathom Pharmaceuticals has brought on another former Celgene exec. Last month the company welcomed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
